Hemp Stocks

770 posts / 0 new
Letzter Beitrag
Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 09.10.2018
Mitglied seit: 16.04.2010
Kommentare: 1'402
Ja, ok, heute auch noch - und

Ja, ok, heute auch noch - und danke. Smile  Dirol

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
Hier noch die letzten News

Hier noch die letzten News (sind von vergangener Woche):

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:WEED-2566437

Also, das wäre abgeschlossen.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
Nun habe ich auch noch mega

Nun habe ich auch noch mega gute News gesehen von heute und mogen kommen dann die Q3-Zahlen:

https://www.newswire.ca/news-releases/canopy-growth-corporation-issues-common-shares-673897823.html

SMITHS FALLS, ON, Feb. 13, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to announce that it has acquired certain intellectual property assets and know-how for total proceeds of  $5,325,250 of which $3,132,500 was paid on closing by issuing 117,253 common shares of the Company based on the 5 day VWAP of $26.7157.  The remaining consideration of $2,192,750 will be paid over a series of milestones in common shares of the Company at the 5-day VWAP when each milestone is achieved.

 

 

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Organa Brands, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands. Canopy Growth operates seven cannabis production sites with over 665,000 square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth......

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
Q3-CGC / 2018

 

Anbei die Zahlen, ist etwas viel, drum s. Link:

https://www.newswire.ca/news-releases/canopy-growth-corporation-reports-third-quarter-fiscal-2018-financial-results-focussed-on-execution-674025453.html

 

Info:

SMITHS FALLS, ON, Feb. 14, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") today announced that it has signed a letter of intent with the Société des alcools du Québec ("SAQ") to provide the Quebec market with 12,000 kilos of high-quality cannabis annually.

This announcement marks Canopy Growth's fourth and largest supply agreement to-date, following previous agreements with the Provinces of New Brunswick, Newfoundland and Labrador, and Prince Edward Island. Three provinces have now announced supply arrangements with Licensed Producers, all of which include Canopy Growth. The Company now has more supply commitments than any other Licensed Producer in the country.

"We've made major investments in the Province of Québec and feel honoured to be chosen to supply the country's second-largest province, and a region we call home, with our wide variety of cannabis products," said Mark Zekulin, President, Canopy Growth. "Signing this letter of intent with SAQ further establishes our dedication to the region and our level of commitment to providing adult consumers in Québec with safe, high-quality cannabis."

Canopy Growth has established a large presence in Québec with the acquisition of Vert Cannabis in Saint Lucien, Québec, and the recent introduction of Vert Mirabel, a Joint Venture with Les Serres Stéphane Bertrand Inc., a large-scale tomato greenhouse operator in Mirabel, Québec.

https://www.newswire.ca/news-releases/canopy-growth-signs-letter-of-intent-with-societe-des-alcools-du-quebec-674024343.html

Presse:

REFILE-Canadian weed producer Canopy Growth posts 123 pct jump in 3rd-qtr revenue

By Nichola Saminather

TORONTO, Feb 14 (Reuters) - Canada’s biggest marijuana producer Canopy Growth said on Wednesday its third-quarter revenue jumped 123 percent to C$21.7 million in the three months ended Dec. 30.

The Smiths Falls, Ontario-based company reported net profit rose to C$11 million, or C$0.01 per share in the three months ended Dec. 30, compared with C$3 million, or C$0.02 a share, a year earlier. The average analyst forecast was for a loss of $7.1 million, or C$0.05 a share.

Reporting By Nichola Saminather Editing by Chizu Nomiyama

Our Standards:The Thomson Reuters Trust Principles.

 

 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
CGC-Zahlen

Mega stark! Ich gratuliere. Habe hier auch noch was gefunden:

http://www.cbc.ca/news/business/canopy-growth-earnings-1.4534697?cmp=rss

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
CGC-News

Anbei mal wieder was Erfrischendes zu lesen von heute:

https://www.newswire.ca/news-releases/canopy-growth-successful-in-bid-to-operate-private-retail-stores-in-manitoba-674278493.html

07:37 ET

SMITHS FALLS, ON, Feb. 16, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to announce that it has been conditionally selected by the Government of Manitoba to operate cannabis retail stores in the province after a rigorous and highly competitive RFP process. Canopy Growth, along with its partner Delta 9, is one of four successful candidates chosen to operate a number of retail locations throughout the province. Further details on locations and store quantities will follow as the RFP process is finalized.

Once official, this will mark Canopy Growth's second provincial retail agreement after previously announcing plans to apply to operate four retail stores in the Province of Newfoundland & Labrador. To date, four provinces in Canada have put forward their retail and supply frameworks including New Brunswick, Newfoundland & Labrador, and Prince Edward Island; and all of them have chosen Canopy Growth as a trusted partner and supplier. Just this week, Canopy Growth also entered into a Letter of Intent (LOI) with the province of Quebec to supply up to 12,000 kg of cannabis in that province annually.

"I would like to commend the Government of Manitoba on choosing a competitive retail model that offers access to a variety of new and existing cannabis brands to Manitobans," said Mark Zekulin, President, Canopy Growth. "We look forward to establishing friendly and modern retail spaces that prioritize consumer education and superior customer service, resulting in a safe and positive experience for adult consumers while introducing them to the best brands Canada has to offer including Tweed, Leafs By Snoop, DNA Genetics and a variety of carefully curated independent CraftGrow partners from around the country."

Canopy Growth is dedicated to promoting education and informed understanding of cannabis. Established partnerships with organizations like MADD Canada and Parent Action on Drugs (PAD) support the Company's goal of entering the legalized recreational market in Canada in a responsible manner. With a focus on customer education and retail training, Canopy Growth aims to ensure adult consumers in the Province of Manitoba will enjoy informed, and safe cannabis experiences provided through a welcoming and informative retail experience.

Here's to Future Growth (in Manitoba).

About Tweed
Tweed is a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell cannabis, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

 

Presse:

https://www.reuters.com/article/brief-canopy-growth-says-conditionally-s/brief-canopy-growth-says-conditionally-selected-by-manitoba-government-to-operate-cannabis-retail-stores-in-province-idUSFWN1Q60QA

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
News

Was uns heute sehr erfreut: Mega gute News von CGC/TWEED

(Nun bin ich mal zuerst damit Wink  I-m so happy  Dirol , aber danke @ Selector für die jeweils nützlichen Infos hier).

 

06:53 ET

 

Share this article

  • Aldergrove Licence Secures Canopy with more than a Million sq. ft. of Licensed Production

ALDERGROVE, BC, Feb. 20, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that it has received a cultivation licence for the first of its two sites operating under the BC Tweed Joint Venture Inc. ("BC Tweed") banner.

-->

Canopy Growth's 1.3 million sq. ft. greenhouse in Aldergrove, BC. (CNW Group/Canopy Growth Corporation)

Canopy Growth's 1.3 million sq. ft. greenhouse in Aldergrove, BC. (CNW Group/Canopy Growth Corporation)

-->

The rapid licensing of the Aldergrove site, the largest federally licensed cannabis site anywhere in the world, continues a pattern of professional execution for the Company as it prepares to meet an unprecedented increase in demand in a few short months once legal adult-use markets commence. The initial licensing covers over 400,000 sq. ft. of growing space, allowing vegetative growth so that the mature plants can be spread into the full 1.3 million sq. ft. in the coming months for flowering and ultimate harvest.

Friday was the culmination of world class execution (and not much sleep) from the Company's BC team with support from teams across the country, as in only a few short months the site was renovated with lighting, shade systems, security, and automated systems to meet the rigorous standards of both the ACMPR and Canopy Growth. Over the weekend, the site received the largest single shipment of cannabis clones in the Company's history, with over 100,000 live cannabis clones flying high from the Tweed Smiths Falls Campus to their new home in British Columbia.

"Our team has made monumental and often historic progress in the retail landscape of every Canadian province to have announced its system to date. We are the only producer in Canada who can make this claim and we will continue to leverage our production platform in order to solidify a truly national presence for our cannabis brands," said Mark Zekulin, President, Canopy Growth. "A cultivation license for our first BC Tweed site positions us to continue this trend as Canada's, and indeed the world's largest, most reliable and most diversified producer and seller of high quality regulated cannabis."

"As proud native British Columbians and long-time horticulture producers we are excited to continue the proud tradition of BC bud on a national scale," said Victor Krahn, who runs operations for BC Tweed. "Working with Canopy Growth we're going to take the Tweed brand to the next level on the West Coast and bring the best our province has to offer to the country and the world."

With the Aldergrove, BC site now into the production stage, BC Tweed's focus will turn to its second BC site, a 1.7 million sq. ft. greenhouse, with work already well under way. With this expansion, Canopy Growth is on track to have over 5.6 million sq. ft. of domestic growing space.

Management consulted IIROC and made the decision to halt trading of Canopy Growth common shares on the TSX on Friday, Feb 16th at approximately 4:20 pm ET when it learned that it had been issued the licence because it represented a material change in the Company's production capacity.

Here's to Future (Sun Grown BC Bud) Growth (from Your Friends at Tweed).

About Tweed
Tweed is a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell cannabis, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

About BC Tweed Joint Venture
BC Tweed Joint Venture is a collaboration between Canopy Growth and an established, large-scale greenhouse grower to develop up to 3 million sq. ft. of high-end, automated greenhouse production space across two sites in beautiful British Columbia. Production is already underway to serve the growing demand for Canopy's family of genetics.

 

Quelle:

https://www.newswire.ca/news-releases/canopy-growth-obtains-license-for-first-mega-scale-bc-facility-674557093.html

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
Nach den kürzlichen

Nach den kürzlichen Gewinnmitnahmen und einer sog. Korrektur, könnte man sich hier wieder etwas vorwärts bewegen. Den Bericht habe ich heute noch gesehen, ist nicht übel geschrieben, klingt für mich nur etwas, als wäre jemand krank gewesen Biggrin war aber nicht, man war hier nur saugut, und nun warten wir auf noch Besseres.

 

Canopy Growth: Neue Plantage, neues Glück? Hoffnung keimt auf!

Von

Björn Pahlke

-27. Februar 2018

Lieber Leser,

die Canopy Growth-Aktie hat in den vergangenen Tagen einen weiteren Verlust verzeichnen müssen. Dennoch gibt es Hoffnung für die Cannabis-Aktie. Die Lizensierung einer neuen Plantage kam bei den Anlegern gut an und könnte den Kurs nach oben drücken.

Nach einem schwachen Jahresstart sind viele Cannabis-Aktien deutlich gesunken. Auch die Canopy Growth-Aktie verzeichnete einen deutlichen Verlust. Anfang des Jahres stand die Aktie noch über 28 €. Jetzt wird die Aktie bei gerade einmal 17,60 € gehandelt. Auch in der letzten Woche war die Aktie eher schwach. Im Vergleich zur letzten Woche hat sie um rund 1,50 € verloren. Die Aktie ist also weiter auf Korrekturkurs.

Diese Aktie geht steil: US-Aktie vor ver-20-fachung! Der Name der Aktie lautet…

Ende letzter Woche gab das Unternehmen aber die Lizenzierung zur Kultivierung einer neuen Plantage in British Columbia bekannt. Aus eigenen Angaben soll es sich dabei um die weltweit größte lizenzierte Plantage handeln. Durch diese Bekanntmachung sollte sich die Preismacht des Unternehmens nach oben bewegen, worauf die Anleger auch positiv reagierten. Canopy Growth könnte sich dadurch einen Vorteil gegenüber seinen Konkurrenten verschaffen.

Fazit: Die Aktie kann weiter keinen Gewinn markieren. Dennoch ist durch die Lizenzierung einer großen, neuen Plantage wieder Hoffnung aufgekeimt. Canopy Growth könnte den Konkurrenten einen Schritt voraus sein......

Quelle:

https://www.finanztrends.info/news/canopy-growth-neue-plantage-neues-glueck-hoffnung-keimt-auf/

 

Ach, noch was, für solche die Lust zum Risiko haben:

Globe says Aphria, rivals seen as global leaders

2018-02-26 08:07 ET - Use of Proceeds

See In the News (C-APH) Aphria Inc

The Globe and Mail reports in its Monday, Feb. 26, edition that Colombia is attracting Canadian investment and global attention for its progressive and research-based policies on marijuana. The Globe's guest columnists Alvaro Torres and Matt Murphy write that in Latin America, after Uruguay, the move to legalize medical pot really began in one of the region's largest economies, with the first licences issued in Colombia in 2017. In recent months, medical-cannabis legislation has also passed in Chile, Argentina and Peru, with politicians seeing the growing and cultivation of cannabis for medical purposes as a viable alternative to the illegal drug trade of a generation ago, and a defence against the opioid crisis seen across Canada and the United States. As Canada's new recreational weed laws come into effect later this year, it is fast being recognized as the leader in the sector in Latin America and around the globe with its expertise in market investment, banking, retail, technology, scientific and medical research. With a combined population of more than 640 million, Latin America offers a vast strategic alternative to the U.S. for Canada to use its financial capital in the medical-marijuana industry.

 

 

 

 

 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
TWEED-Modeshow

BiggrinDirol  Das wird sicher interessant, schade kann ich nicht dabei sein, aber vielleicht gibt es ja ein Video?

Quelle:

https://www.newswire.ca/news-releases/tweed-to-present-a-collaborative-fashion-show-at-toronto-mens-fashion-week-fallwinter-2018-675805043.html

News provided byCanopy Growth Corporation

07:00 ET

 

Bringing together 18 Canadian designers, Tweed: Fabric of Creativity will highlight the intrinsic similarities between the fashion and cannabis industries

TORONTO, ON, March 5, 2018 /CNW/ - Tweed Inc. ("Tweed") is proud to present a collaborative fashion show at TOM* F/W this coming week. Over the past four years, Tweed has grown and sold thousands of kilograms of legal, high-quality cannabis products to medical customers across the country, always staying true to its roots and personality as an approachable, proudly Canadian producer. 

 

 

On the evening of March 9, 2018, working in collaboration with some of Canada's top clothing designers, Tweed is set to present its first ever runway show, Tweed: Fabric of Creativity, at Toronto Men's Fashion Week. The show will feature 36 designs by 18 of Canada's top talents, and will showcase the Tweed personality to a new, equally discerning audience.

Tweed: Fabric of Creativity will showcase the immense talents of designers Zane Barlas, NICO, Xian, Pascal Labelle, Candace Daniela, Tristan Licud, Nabeel Sheikh, JM Trends, Joseph Tassoni, Shelli Oh, Kristian Nielsen, Thomas Henry, Austen Dor, WRKDEPT, L'MOMO, Get Fresh Company, Ross Mayer, and FARLEY CHATTO.

The designers and their teams have been tasked with creating ensembles that combine both tweed fabric as well as their interpretation of the essence of the Tweed brand for the runway show.

The fashion show is just one component of Tweed's participation in Toronto Men's Fashion Week. For the duration of TOM* (March 9 to 11, 2018), as well as its sister event, Toronto Women's Fashion Week (March 12 to 14, 2018), Tweed will have an on-site informational exhibit so that the adult, fashion community can get to know who we are as Canadian leaders and proud cannabis connoisseurs.

Tweed was founded with the belief that cannabis can be a force for good. Not something that should be hidden, but something which deserves informed, open dialogue. Whether through doctor education, our celebrated Artists in Residence program, or fashion week, Tweed supports the communities in which it is present.

"With brand names like Argyle and Herringbone, we are excited to finally engage with the diverse and creative fashion community to bring our personality to life, enriching the fabric of Tweed through dialogue and engagement," said Bruce Linton, co-founder and CEO of Tweed. "This is an exciting time and an exciting project for Tweed."

Tweed: Fabric of Creativity takes place Friday, March 9, 2018 at 9pm during Toronto Men's Fashion Week at 1 Yonge Street.

About Tweed
Tweed is a wholly owned subsidiary of Canopy Growth Corporation (TSX:WEED) and a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn't just sell cannabis, it facilitates a conversation about a product we've all heard about but haven't met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, its subsidiaries, or its affiliates to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canopy Growth Corporation

For further information: interview requests with Tweed`s Director of Marketing Amy Wasserman or any of the 18 featured designers, designer sketches, and hi-res photography, please contact: Brill Communications at 416-533-6425; Desia Halpin-Brill, desia@brillcommunications.ca; Myriam Tardif, myriam@brillcommunications.ca

Related Links

http://canopygrowth.com/

Emil

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 09.10.2018
Mitglied seit: 16.04.2010
Kommentare: 1'402
CGC

 

Das würde mich auch interessieren.

 

Zufällig bin ich heute noch auf folgenden Bericht gestossen:

https://www.profitconfidential.com/stock/canopy-growth-stock/canopy-growth-stock-forecast-weed-stock-nasdaq/

 

WEED Stock: Canopy Growth Eyeing Nasdaq Listing Is Good News

 

By Stephen Karmazyn Published : March 5, 2018

Canopy Growth Stock Forecast

There’s a new buzz surrounding marijuana stocks and for once, it doesn’t have anything to do with legalization or really marijuana at all. Instead, this wave of excitement is being propelled by what is otherwise pretty standard fare: stock market listing choices.

Many companies are now eyeing a Nasdaq index listing to help boost their stock prices, with Canopy Growth Corp (OTCMKTS:TWMJF, TSE:WEED) having made public its plans to land on itself on the Nasdaq. With the TWMJF stock price today sitting at a hair under $23.00, Canopy could be in store for a serious jump in value should it be able to migrate its listing to a big U.S. stock market like the Nasdaq.

This goes beyond speculation. Proof is readily available by way of Cronos Group Inc (NASDAQ:CRON), which last week became the first Canadian marijuana stock to list itself on the Nasdaq. As a result, the company shot up about 35% in five days.

The simple fact is that there is a lot of untapped capital waiting in the U.S. held by investors eager to get into the marijuana market but leery of over-the-counter stock buys or the Canadian stock exchanges. Considering that marijuana is still making the transition—at least in the public eye—from illicit drug to legal commodity, many investors want the comfort of legitimacy that a massive stock exchange like the Nasdaq connotes.

This isn’t to say that the Canadian exchanges are illegitimate. But they simply don’t have the heft of the Nasdaq, nor do they have the same amount of influence. Being on the Nasdaq, for many investors, essentially announces to the world that a company is safe, legitimate, and ready to be traded. In this case, whether or not that is true is irrelevant. It’s all about perception in the eyes of investors, many of whom may not be familiar with the marijuana stock market and therefore are taking cautionary approaches to putting money in pot stocks.

And that brings us to the Canopy Growth stock forecast.

The company is already one of my personal favorites in the industry, due to its international focus, strong foundations as the largest player in the market, and what has been a strong year for the company in terms of numbers, if not stock value.

Chart courtesy of StockCharts.com

While the WEED stock forecast in 2018 has been muted so far as a result of a harsh correction that took place in mid-January and continued through February, the rest of the year is shaping up to be a strong one for marijuana as Canadian recreational pot legalization is set to roll in during the summer.

Aside from that, companies like Canopy Growth have begun centering their attention on European markets as medical marijuana is becoming more readily available on the continent.

The company recently scored a big win in Germany, with sales topping seven figures for the first time. (Source: “Canopy Growth doubles cannabis sales, while MedReleaf takes smaller strides,” Financial Post, February 14, 2018.)

The company also inked a deal with Constellation Brands, Inc. (NYSE:STZ), a major U.S. liquor company, valued at CA$245.0 million.

Its most recent earnings report also yielded big numbers, with a year-over-year registered patient growth of 138%. Revenue skyrocketed by 123% to reach CA$21.7 million, up from CA$9.8 million.

So I already marked a positive Canopy Growth stock forecast, which has only become more bullish since the company announced plans to take its listing to the Nasdaq.

With marijuana stocks all looking to gain a competitive edge on each other in what is one of the most exciting and fasting growing industries around, landing itself on the Nasdaq would pay huge dividends to WEED stock.

Like Cronos, Canopy would likely be the recipient of a nice, fast boost in stock value in the direct aftermath of a Nasdaq listing. While that rush will likely end in a correction, I believe that the stock will, on balance, have gained several percentage points overall in a short period of time, with as high a gain as 10%+ in a week when all the smoke clears.

Beyond that short burst of value, the company will also become the target of investment by many formerly skittish American investors. That new influx of capital could lead to significant gains for the stock. Of course, too fast of a leap will eventually lead to a correction due to fear of overvaluation, but again, I suspect that, on balance, Canopy Growth stock will come out ahead.

“When Constellation put money into our business, the number of U.S. institutional investors interested in us went way up,” Canopy Growth Chief Executive Officer Bruce Linton said at the Economic Club of Canada last week. “The Nasdaq is doing a great job not allowing people to list who break federal laws and that’s a place where we should list in due course.” (Source: Canadian weed producer Canopy should list on Nasdaq ‘in due course’: CEO,” Reuters, March 1, 2018.)

Linton said that Canopy was intent on putting itself on the Nasdaq as far back as October, but it wanted to sort out its deal with Constellation before making the move.

“We prepared to list in October and we pulled it back, because trying to do the deal with Constellation was already 11 months of complexity,” he said. (Source: “Canopy Growth eyes potential Nasdaq listing,” The Financial Post, March 1, 2018.)

“The step will be list — and get ready for the drum roll — there will be a $75-million U.S. placement-ish. And it’s just because the economic model works for the people who took you public and give you coverage to get a listing out there.”

Ultimately, it does look like a Nasdaq listing is in the cards for Canopy, and that is great news for Canopy Growth stock investors. And, as Linton’s remarks show, the company is clearly interested in gaining more attention from U.S. investors, which is the right move in my estimation.

Analyst Take

With so many concerned over a U.S. marijuana crackdown, it makes sense why people would want to see companies listed on the Nasdaq before they put their money in. There’s a lot of uncertainty concerning how the U.S. views marijuana (which I’ve devoted considerable virtual column inches to).

While I believe that the talk about a U.S. attack on marijuana is ultimately far more smoke than fire, it is still a possibility and therefore a perfectly valid reason for more cautionary investors to take their time before rushing into the marijuana market.

But when you consider the Canopy Growth stock forecast, there is a price for waiting as well. I believe that the company is poised to see big gains throughout 2018, with a Nasdaq listing and Canadian marijuana legalization being two separate but potentially powerful events for the stock, with massive gains a possible outcome.

In both cases, we’re also likely to see wild swings both up and down, but I believe that will all end with a Canopy Growth stock that is stronger tomorrow than it is today.

Investors may want to keep an eye out for when Canopy Growth appears ready to list on the Nasdaq because a big stock boost will likely follow.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
CGC / Video

Wie gewünscht.  GoodWinkSmile .  Super, wir bekommen in den nächsten Wochen einige Short-Videos, damit wir auch dabei sind und mitverfolgen können.

https://www.youtube.com/watch?v=c9qhIX7Kk_c  

Best regards,  

Tyler Burns

Investor Relations

Canopy Growth Corporation

C: 613-697-0367

T: 613-706-2185 ext. 122

www.canopygrowth.com

 

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
CGC

 

Ich sehe heute Erfreuliches hier und poste euch anbei aktuelle News:

Quelle:

https://www.newswire.ca/news-releases/canopy-growth-completes-genetics-transfer-to-spain-and-provides-update-on-spanish-operations-and-partnership-677245293.html

 

News provided byCanopy Growth Corporation

07:00 ET

    -->

SMITHS FALLS, ON and MADRID, March 19, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") is pleased to confirm that it has successfully completed a transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA ("Alcaliber"), completing the first phase of a partnership entered into by both parties (the "Parties") as announced on September 11, 2017.

-->

Healthy cannabis clones have arrived in Spain (CNW Group/Canopy Growth Corporation)

Healthy cannabis clones have arrived in Spain (CNW Group/Canopy Growth Corporation)

-->

Canopy Growth and Alcaliber enjoy a very strong and committed partnership which will continue to see Alcaliber producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes.

Canopy Growth also wishes to clarify that, contrary to certain speculation, the Company is not in negotiations to acquire Alcaliber.

"Our view of the European continent mirrors our Canadian expansion strategy," said Bruce Linton, Chairman and CEO, Canopy Growth. "We're diversifying our production capabilities on the continent in anticipation of rapid European market expansion. In addition to a large licenced production footprint in Odense, Denmark we are working closely with our partner Alcaliber to capture market share by scaling supply."

The successful transfer marks the third continent with Canopy Growth genetics growing in soil today.

Here's to Future Growth (not just export) in Europe and beyond.

 

Presse:

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:WEED-2582814

Canopy completes transfer of 1,500 clones to Alcaliber

2018-03-19 07:47 ET - News Release

Mr. Bruce Linton reports

CANOPY GROWTH COMPLETES GENETICS TRANSFER TO SPAIN AND PROVIDES UPDATE ON SPANISH OPERATIONS AND PARTNERSHIP

Canopy Growth Corp. has successfully completed a transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA, completing the first phase of a partnership entered into by both parties as announced on Sept. 11, 2017.

Canopy Growth and Alcaliber enjoy a very strong and committed partnership which will continue to see Alcaliber producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes.

Canopy Growth also wishes to clarify that, contrary to certain speculation, the company is not in negotiations to acquire Alcaliber.

"Our view of the European continent mirrors our Canadian expansion strategy," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "We're diversifying our production capabilities on the continent in anticipation of rapid European market expansion. In addition to a large licensed production footprint in Odense, Denmark, we are working closely with our partner Alcaliber to capture market share by scaling supply."

The successful transfer marks the third continent with Canopy Growth genetics growing in soil today.

About Canopy Growth Corp.

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates seven cannabis production sites with over one million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The company has operations in seven countries across four continents.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
Info

Ich habe erst jetzt gesehen, dass wir noch News bekommen haben, supergute und es freut, dass hier soviel entsteht und wächst!

 

Canopy to develop pot-based medicines with Beckley

2018-04-09 06:46 ET - News Release

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:WEED-2591379

Mr. Bruce Linton reports

GLOBAL CANNABIS RESEARCH LEADERS BECKLEY FOUNDATION AND CANOPY HEALTH INNOVATIONS PARTNER TO FORM BECKLEY CANOPY THERAPEUTICS

Canopy Growth Corp. has launched Beckley Canopy Therapeutics, a partnership between its affiliate and biopharmaceutical research arm Canopy Health Innovations and drug research pioneer Lady Amanda Feilding and the Beckley Foundation.

Beckley Canopy has been formed to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. The partnership will combine Amanda Feilding's plus-20-year record of groundbreaking research and network of world-renowned scientific collaborators with Canopy Health's leadership in the commercial cannabis and pharmaceutical industries, bringing together European and North American based research leaders in cannabis.

"We are delighted to have formed this partnership with Beckley. They have been leading the way in drug policy reform and cannabis research for more than two decades and we feel that our skill sets complement each other perfectly," said Marc Wayne, chief executive officer of Canopy Health. "This is a unique opportunity to expand our operations, conduct world-class research, and meet the needs of doctors and patients around the world."

As part of its business model, Beckley Canopy will engage in a number of research areas to establish an intellectual property portfolio and develop innovative cannabis-based pharmaceutical and natural health products. In doing so, it plans to work with cannabis genetics and other products provided by its strategic partner, Canopy Growth, the largest cannabis company in the world.

"For over half a century, I have been committed to scientifically investigating the potential benefits of certain psychoactive compounds for the treatment of illnesses and for the enhancement of well-being," said Amanda Feilding, founder and executive director of the Beckley Foundation. "Twenty years ago, I set up the Beckley Foundation in order to bridge the divide between science and drug policy. We have come a very long way since then and have now begun an exciting new chapter where science can be used to provide safe and effective cannabis medicines for people in need all over the world. I am thrilled to have Canopy Health as our partners in this new venture. I have great faith not only in their capabilities but also in their commitment to maintaining the Beckley Foundation's ethical standards in everything we do together."

Staying true to both partner organizations' commitment to corporate social responsibility, Beckley Canopy will donate a share of all profits from future commercialized products to support the not-for-profit scientific research and policy work of the Beckley Foundation.

Beckley Canopy's first intellectual-property-generating research in humans is already under way: a brain imaging trial looking at the effects of a proprietary cannabinoid formulation in the treatment of a major indication. Additional research and product development programs are scheduled to start in 2018. As IP positions are secured, further information will be provided.

Here's to future (scientific research) growth.

About Canopy Growth Corp.

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates seven cannabis production sites with over one million square feet of production capacity, including over 500,000 square feet of GMP-certified production space.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

 

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
CGC / Liefervereinbarung

Heute wieder gute News Smile  Dirol  (war kurz weg, danke für die Info @ Emil)

Presse:

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:WEED-2592370

Canopy Growth completes three year supply agreement with the Société des alcools du Québec

Canada NewsWire

SMITHS FALLS, ON, April 11, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) today announced that it has completed a three year supply agreement with the Société des alcools du Québec ("SAQ") for 12,000 kgs of high-quality cannabis products.

Securing this long term agreement marks another important step in preparing for a legal recreational market in the province of Quebec, and builds upon the letter of intent signed in early February of this year.

"This agreement is an exciting next step in delivering a wide range of our safe, high-quality products to consumers across the province," said Mark Zekulin, President, Canopy Growth. "Quebec is home for Canopy Growth and we're proud to be advancing this long term partnership to develop the Québec market."

Canopy Growth has well-established presence in the province of Québec through its wholly- owned subsidiary Vert Cannabis in Saint Lucien and Vert Mirabel, a company recently formed with Canopy Rivers and Les Serres Stéphane Bertrand Inc., a large-scale greenhouse operator in Mirabel. The 700,000 sq. ft. greenhouse at Vert Mirabel is currently being retrofitted and optimized for cannabis production.

The supply agreement is conditional upon the federal and provincial governments adopting the necessary regulatory framework. 

This agreement is a milestone of significance for the Canadian cannabis industry as a whole and accordingly, congratulations are in order for other licensed producers who have completed their first agreements with the SAQ, marking a truly historic day for the sector.

Quelle:

https://web.tmxmoney.com/article.php?newsid=5914099085737154&qm_symbol=WEED

 

 

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 15.10.2018
Mitglied seit: 10.11.2015
Kommentare: 104
Trump Overrules Sessions:

Trump Overrules Sessions: Promises To Protect States' Pot Legalization Rights

Three months after AG Sessions rescinded policies allowing states to legalize pot, President Trump has defused standoff with a top Republican (Colarado's Cory Gardner) and promised that he will support congressional efforts to protect states that have legalized marijuana.

  • 9287
  • Apr 13, 2018 1:48 PM

.....kann man nur hoffen dass aus dem Hü nicht wieder ein Hott wird.....

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
Neue Parterschaften

Ja Petra, das weiss man dort eben nie so genau...

https://www.newswire.ca/news-releases/canopy-growth-corporation-announces-acquisition-of-largest-czech-medical-cannabis-company-annabis-medical-679801443.html

 

16.04.2018 | 14:13

Smiths Falls, Ontario und Prag, Tschechische Republik (ots/PRNewswire) -

Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" oder das "Unternehmen") freut sich anzukündigen, dass das Unternehmen endgültige Verträge zur Übernahme von Annabis Medical s.r.o ("Annabis Medical") unterzeichnet hat und damit den Fokus des Unternehmens in einen weiteren aufstrebenden Markt für medizinisches Cannabis erweitern wird. Dieses Geschäft soll am Montag, dem 16. April 2018 zum Abschluss gebracht werden.

Annabis Medical ist in der Tschechischen Republik Branchenführer für medizinisches Cannabis und importiert und vertreibt derzeit Cannabis-Produkte für den Verkauf über den Apotheken-Vertriebskanal im Rahmen tschechischer Lizenzen in der Tschechischen Republik. Sein Gründer und CEO, Dr. Robin Kazík, wird auch weiterhin das tschechische Tochterunternehmen als Teil der größeren Canopy Growth-Familie leiten und voranbringen.

"Diese Übernahme ist ein weiteres Beispiel für unser Engagement, die Präsenz von Canopy in Europa zu erweitern und unsere Führungsposition auszubauen", sagt Mark Zekulin, President von Canopy Growth. "Wir freuen uns darauf, tschechische Kunden mit unseren hochwertigen medizinischen Cannabis-Produkten aus GMP-Produktion zu beliefern und weitere Ressourcen zur Unterstützung der Weiterbildung tschechischer Apotheker, Patienten und medizinischer Fachkräfte bieten zu können."

Durch die Kombination des weitreichenden globalen Erfahrungsschatzes und Netzwerks mit der starken nationalen Position von Annabis Medical ist Canopy stolz, seine renommierte Marke Spectrum Cannabis auf einen weiteren europäischen Markt zu bringen.

"Mit einer soliden Präsenz und einem etablierten Vertriebsnetz auf dem tschechischen Markt für medizinisches Cannabis, sowie aufgrund der langjährigen Erfahrung beim Import von Cannabis aus Kanada freuen wir uns, zur Canopy Growth-Familie zu stoßen. Dieser Schachzug wird es uns ermöglichen, unser Produktangebot noch schneller zu diversifizieren, und unseren Zugang zu Rohmaterialien stärken, wenn wir im Markt wachsen", sagte Dr. Robin Kazík, Gründer und CEO von Annabis Medical.

Die Übernahme von Annabis Medical baut auf der Führungsposition von Canopy Growth im europäischen Segment für medizinisches Cannabis auf und folgt der kürzlich zustande gekommenen Partnerschaft und dem Liefervertrag mit dem führenden spanischen Pharmaunternehmen Alcaliber S.A. Darüber hinaus beliefert Canopy Growth derzeit schon den deutschen Markt über sein Tochterunternehmen Spektrum Cannabis GmbH und ist eine Partnerschaft mit Spectrum Cannabis Denmark ApS eingegangen, das über eine Lizenz für den Anbau von Cannabis in einer 40.000 Quadratmeter großen Treibhaus-Produktionseinrichtung in Odense, Dänemark, verfügt. Diese Aktiva, in Kombination mit den unvergleichlichen Produktions- und Vertriebsplattformen von Canopy Growth in Kanada, ergeben die am stärksten diversifizierte Cannabis-Plattform der Welt.

Gemäß den Vertragsbestimmungen wird das Unternehmen bei Abschluss 50.735 Stammaktien aus dem Eigenkapital mit einem Wert von CAD 1.491.882,70 an Dr. Kazík ausgeben und wird, vorbehaltlich der Erreichung bestimmter Meilensteine, bis zu 34.758 weitere Stammaktien mit einem Wert von CAD 1.022.080,00 (Basis 5-Tages-VWAP von CAD 29,40519 am 5. April 2018) ausgeben. Der Gesamtwert der im Rahmen des Vertrags zu zahlenden Vergütung beträgt ca. CAD 2.513.962,70. Sämtliche Beträge sind, soweit nicht anderweitig aufgeführt, in Kanadischen Dollar (CAD) angegeben.

 

Über Annabis Medical s.r.o

Annabis Medical s.r.o ist ein in der Tschechischen Republik ansässiger Lieferant von medizinischem Cannabis und hält seit 2014 entweder unmittelbar oder über Tochtergesellschaften Lizenzen für medizinisches Cannabis. Der Vertrieb von medizinischem Cannabis begann 2015, wobei das Unternehmen schon vorher mit Office of Medicinal Cannabis aus den Niederlanden zusammengearbeitet und zudem medizinisches Cannabis aus Kanada importiert hatte. Das Schwesterunternehmen Annabis, s.r.o. stellt Biokosmetik auf Hanfbasis her und ist nicht in die Transaktion involviert.

Jordan Sinclair, Director of Communications, Jordan@tweed.com, +1-613-769-4196; Investor Relations: Tyler Burns, Tyler.Burns@canopygrowth.com , +1-855-558-9333 ex 122; Director: Bruce Linton, tmx@tweed.com

OTS: Canopy Growth Corporation newsroom: http://www.presseportal.de/nr/121334 newsroom via RSS: http://www.presseportal.de/rss/pm_121334.rss2

© 2018 news aktuell

 

DELTA, BC, April 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that yesterday it received additional licensing at both greenhouse facilities operating under its majority-owned BC Tweed Joint Venture banner, including the licensing of the largest cannabis facility in the world.

In particular, the already operating 1.3 million sq. ft. greenhouse facility in Aldergrove, BC, where 400,000 sq. ft. of canopy under glass was licensed in February, is now licensed for 840,000 sq. ft. of growing space.

The second BC Tweed site, totalling 1.7 million sq. ft. of greenhouse production space, also received a cultivation licence for its first 900,000 sq. ft. of growing space.

In total, Canopy Growth's licensed growing space has tripled in calendar 2018, to more than 2.4 million sq. ft. and remains on path to exceed 5.6 million sq. ft. of domestic growing space.

In consultation with IIROC and as a best practice, the Company decided to halt trading of its common shares on the TSX as soon as the licensing news was made public as the increased production capacity represents a material change in operations.

"This is all about focus and execution for our expanding team at Canopy Growth," said Mark Zekulin, President, Canopy Growth. "We have spent four years establishing the largest licensed cannabis production platform in the world. This afternoon with two key licensing milestones, we doubled it."

Want to learn more about our team at BC Tweed: visit us here.
https://www.youtube.com/watch?v=c9qhIX7Kk_c

Here's to Future (BC) Growth (and BC Bud).

 About BC Tweed Joint Venture
BC Tweed Joint Venture is a collaboration between Canopy Growth and an established, large-scale greenhouse grower to develop up to 3 million sq. ft. of high-end, automated greenhouse production space across two sites in beautiful British Columbia. Production is already underway to serve the growing demand for Canopy's family of genetics.

 

 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
CGC / Patente

Ich sehe noch eine Info vom Montag und finde die wissenswert:

Canopy Growth's Canopy Health files provisional patents

2018-04-23 08:23 ET - News Release

 

Mr. Bruce Linton reports

CANOPY HEALTH INNOVATIONS FILES A SUITE OF ADDITIONAL CANNABIS-RELATED PATENTS

Canopy Health Innovations, the partly owned biopharmaceutical research and development affiliate of Canopy Growth Corp., has, alone or with its subsidiary Canopy Animal Health or through its joint venture Beckley Canopy Therapeutics, filed eight provisional U.S. patents pertaining to the delivery and application of cannabis and cannabinoid-based therapeutics in certain indications.

Specifically, the eight patent applications relate to the following:

 

  • Fibromyalgia;
  • Amyotrophic lateral sclerosis (also known as ALS, Lou Gehrig's disease);
  • Anxiety and its various subgroups (in humans and animals, in conjunction with Canopy Animal Health);
  • Cognitive enhancement (in humans and animals, in conjunction with Canopy Animal Health);
  • Pain and various subgroups (in humans and animals, in conjunction with Canopy Animal Health);
  • Opioid sparing, pain management and addiction (through Beckley Canopy Therapeutics);
  • Addiction and smoking cessation (through Beckley Canopy Therapeutics);
  • A platform and method for delivery of cannabis-based compositions.

 

In addition to updated applications relating to earlier Insomnia patent applications, this brings the total number of U.S. provisional patent filings (including Canopy Animal Health and Beckley Canopy Therapeutics) to 39.

These filings are part of a concerted plan to bring to patients and health care providers innovative medicines and health products targeting disease areas with substantial medical needs. As part of this plan, Canopy Health and its affiliates are collaborating with respected world-class academic researchers and clinicians, and working with leading research organizations and regulators in jurisdictions of interest to develop and register these breakthrough products.

"As global medical markets emerge the trend among regulators favours highly regulated and highly repeatable medical cannabis options," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "Through Canopy Health's work we are bulding a body of knowledge around cannabinoid medicine that will lead to its inclusion in mainstream health care for the benefit of patients."

Canopy Health and its affiliates continue their practice of filing provisional patents in the United States, which is common in the field of intellectual property generation and protection. Patents are first filed in the United States to create a priority date and allow for future filings in other selected jurisdictions, including Canada.

Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most common "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids.

Here's to future growth.

Quelle: http://www.stockwatch.com/News/Item.aspx?bid=Z-C:WEED-2596698

 

Smile  Dirol

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
Aktuell

Heute bin ich mal mit aktuellen und erfreulichen News dabei:

https://www.newswire.ca/news-releases/canopy-growth-launches-spectrum-australia-with-support-from-the-victoria-state-government-680869711.html

SMITHS FALLS, ON and MELBOURNE, Australia, April 25, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to join the Victoria State Government in announcing the launch of the newest member of the Canopy Growth family, Spectrum Cannabis Australia ("Spectrum" or "Spectrum Australia").

Minister for Agriculture, the Hon. Jaala Pulford, alongside Ben Quirin, Managing Director of Spectrum Australia, announced the Company will invest up to $16 million AUD (~$16 million CAD) in the State of Victoria over the next four years to establish Spectrum's Asia-Pacific (APAC) headquarters and research and development facility.

"The State Government of Victoria has been an outstanding partner and welcomed our investment in the region with a shared passion for innovation in the medical cannabis industry," said Ben Quirin, Managing Director, Spectrum Australia. "Victoria is now home for Spectrum as we introduce our world renowned medical cannabis products to the State, across Australia, and throughout the entire APAC region as jurisdictions establish legal, regulated medical cannabis regimes."

The Victoria facility will enable domestic cultivation and production of high quality medical cannabis for patients while serving as a distribution hub for other jurisdictions in APAC. It will also operate as the APAC Research and Development Center for the Company, supporting the ongoing research collaboration between Spectrum Australia and Agriculture Victoria on innovations in medical cannabis cultivation and production.

"Collaborating with international experts on cultivation and manufacturing will build Victoria's capacity to develop our medicinal cannabis industry to be able to supply reliable and high quality medicinal cannabis products," said Minister for Agriculture, the Hon. Jaala Pulford.

The launch of Spectrum Australia builds on Canopy Growth's leadership position in the global medical cannabis space. Spectrum Australia's priority is to improve the lives of patients. This goal will be accomplished by focusing on three core areas:

  1. Ensuring an affordable and consistent supply of medical cannabis is available to patients in Australia
  2. Building production and research infrastructure in Australia
  3. Engaging in rigorous evidence-based physician and pharmacist education to ensure patients' access needs are met

This week Canopy Growth renewed its commitment to Australian partner, AusCann (ASX:AC8). Together with the State Government of Victoria and our strong local partner Spectrum Australia is committed to building an industry for the benefit of patients and healthcare professionals throughout APAC. 

Spectrum Cannabis - Medical Cannabis. Simplified.

Learn more by visiting spectrumcannabis.com.au

About Spectrum Cannabis 

Spectrum is an international cannabis business dedicated to improving the lives of patients and increasing cannabinoid knowledge within physician communities around the world. Its colour-coded strain classification system is available in Canada with operations underway in the European Union and South America, and Australia. Spectrum products are available in a range of potencies and formats designed to simplify the dialogue around strength and dosage by categorizing medical cannabis according to THC and CBD levels. Spektrum Germany Gmbh processes cannabis for sale in Germany in a GMP-certified facility and then distributes products to hundreds of German pharmacies. Spectrum Denmark is a partnership between Canopy Growth and Danish Cannabis. Through the partnership, Spectrum Denmark is developing a large-scale greenhouse facility in the city of Odense. Learn more at www.spectrumcannabis.com.au

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eight cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 28.09.2007
Kommentare: 3'102
CGC

Latest News, super (Man sollte wohl mal wieder eine rauchen...) Blum 3Dirol

https://www.newswire.ca/news-releases/cannabis-strain-from-invictus-ab-laboratories-now-for-sale-on-canopy-growth-corporations-tweed-sales-platform-682375962.html

VANCOUVER, May 11, 2018 /CNW/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA: 8IS1) is pleased to announce that cannabis from the company's AB Laboratories Inc. (AB Labs) is now available for purchase through Canopy Growth Corporation's (TSX: WEED) Tweed Main Street online store and to-date AB Labs has transferred 172 KG of product to Canopy.

The strain Super Critical is available now as part of Tweed's elite CraftGrow line, and AB Labs anticipates shipping their other strains in the near future.

 

 

"Canadian medical cannabis patients value product diversity and we're committed to offering them an industry leading curated lineup from Tweed and our CraftGrow partners," said Mark Zekulin, President, Canopy Growth. "We're excited to welcome AB Labs product as the newest CraftGrow addition to the Tweed Main Street online store".

"The Canadian cannabis industry is diverse, dynamic and thriving, with valuable partnerships being forged every day," said Invictus founder and CEO Dan Kriznic. "Our collaboration with Canopy has already been enormously fruitful and rewarding. We look forward to working closely with this model of entrepreneurial fitness and efficiency as Canada's commercial cannabis market develops in coming months and years. I'm pleased to report that Invictus remains on track for achieving its substantial cultivation and harvest goals across 2018, and delivers more and more strains and cannabis volume into Canada's thriving consumer marketplace as Canada approaches legalization of the adult market. To further accommodate this the Company has developed a multifaceted sales strategy aimed to target each channel for sales and distribution such as establishing supply agreements and product calls with provincial governments and licensed producers, developing retail storefronts across Western Canada, and continuing to focus on the medical cannabis sector."

Tweed's highly curated CraftGrow line works only with top producers cultivating Canada's finest cannabis, and AB Labs is honored to have been the second cultivator to successfully transfer cannabis products to be sold though the e-commerce platform.

The Super Critical strain from AB Labs available on the platform is a high-yielding 50/50 hybrid of sativa and indica, a mix of Big Bud, Skunk and White Widow. The combination of exceptional yield plus superb flower makes it a favorite among growers.

AB Labs continues to make continuous progress on its 40,000 square foot Phase 2 facility, which once completed AB Labs will total 56,000 square foot of production capability.  To-date in Phase 2 the interior demolition has been completed, cleaned and sanitized and all upgrades to the electrical and HVAC systems have also been completed. Construction of the mezzanine level has begun and overall progress is according to plan.

About Invictus

Invictus owns and operates cannabis companies in Canada with the vision of producing a variety of high quality and low cost cannabis products and strains to the global market place as regulations permit. Gene Simmons, music legend and media mogul, conveys the vision of Invictus as the Chief Evangelist Officer.

Invictus operates two cannabis production sites under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") in Canada and has over 95,000 square feet of cannabis production capacity at the licensed production sites.  The Company's wholly owned subsidiary Acreage Pharms Ltd. ("Acreage Pharms"), located in West-Central Alberta on 150 acres, has approximately 40,000 square feet of cannabis ready production with its recently completed Phase 2 expansion.  The Company intends on expanding to 120,000 square feet by the end of 2018 once Phase 3 is complete. 

Invictus also owns 50% of AB Laboratories Inc. ("AB Labs"), a licensed producer under the ACMPR located in Hamilton, Ontario. AB Labs currently operates in a 16,000 square foot facility and recently acquired a facility adjacent to the existing property that will allow for a total of 56,000 square feet of cultivation space expected to be ready for production by June 2018. During the first quarter of 2018 AB Labs submitted a secondary license to Health Canada for a nearby property on 100 acres under the name AB Ventures Inc. ("AB Ventures").

Combined, the licensed producers owned by Invictus expect to have approximately 200,000 square feet of cannabis production capacity by the end of 2018 and 520,000 square feet of cannabis production capacity by the end of 2019.

In addition to the ACMPR licenses, the Company has an 82.5% investment in Future Harvest Development Ltd. a high quality Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia that has been in operation for over 20 years under the brand Plant Life Products and Holland Secret.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Emil

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
CGC/TWEED

 

Ich habe heute zwei Nachrichten. Eine finde ich gut, die andere finde ich für mich nicht so beruhigend.

Nun, dies ist die gute Nachricht:

SMITHS FALLS, ON, May 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that it has entered into a non-binding agreement (the "Agreement") to purchase, subject to certain conditions, the remaining 33% stake of BC Tweed Joint Venture Inc. ("BC Tweed") not currently owned by the Company.  The consolidation of the two largest licensed cannabis facilities in the world into full Canopy Growth ownership cements the Company's commitment to shareholder value through scale production.

Canopy Growth, upon closing of the transaction, will issue up to $374 million worth of shares in the Company, subject to the satisfaction of certain conditions, to the minority shareholders of BC Tweed (the "Operators"). Payments are milestone-based and will be released over four years based upon the achievement of certain production milestones. The Operators, multi-generational cultivators, will continue to manage the BC-based operations for a period of 5 years.

The BC Tweed greenhouses represent a meaningful share of the entire Canadian production landscape with up to 3 million square feet of greenhouse growing capacity. Since the formation of BC Tweed in October of 2017, already over 1.7 million square feet has been licensed for production to meet to oncoming recreational cannabis demand across the country.

"Our provincial distribution agreements, commitment to quality and value-add processing, and leading brand portfolio position Canopy Growth as the market share leader in Canada's future recreational cannabis market," said Bruce Linton, Chairman & CEO, Canopy Growth. "Consolidating BC Tweed fully under the Canopy ensures that the full value of our strategic position is realized by Canopy shareholders."

Under the terms of the Agreement, subject to approval of the Toronto Stock Exchange and certain other conditions, the Company will issue $374 million worth of common shares in the capital of the Company based on the volume weighted average price per common share for the 20 trading day period ended May 11, 2018 (the "VWAP"). The Company will also pay $1 million in cash as a non-refundable deposit against the purchase price. In addition, the Company will issue $20 million worth of common shares in the capital of the Company at the same VWAP in connection with an option to acquire certain future infrastructure from the Operators, subject to certain conditions.  The transaction is anticipated to close in early July, following the negotiation of definitive agreements.

 

Und diese hier, naja, ist Vertrauenssache, finde ich.-  Dirol

SMITHS FALLS, ON, May 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company")(TSX: WEED) announced today it has applied to list its common shares on the New York Stock Exchange (the "NYSE").

The Company currently anticipates that, subject to the receipt of all required approvals, its common shares will begin trading on the NYSE before the end of May 2018. In advance of listing on the NYSE, Canopy Growth will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company's common shares on the NYSE remains subject to the approval of the NYSE and the satisfaction of all applicable listing and regulatory requirements.

Canopy Growth's common shares will trade on the NYSE under the ticker symbol "CGC" and will continue to trade on the TSX under the ticker symbol "WEED". A trading date will be made public once all regulatory formalities are satisfied.

In announcing the application to list on a U.S. stock exchange, Canopy Growth's Chairman & CEO, Bruce Linton, commented: "Since becoming the first regulated cannabis producer to list their shares in North America in 2014 our team has focused on building credibility through consistent execution. Once finalized, listing our shares on the NYSE will represent a continuation of our upward trajectory as we build the global cannabis industry."

 

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 09.10.2018
Mitglied seit: 16.04.2010
Kommentare: 1'402
Aurora Cannabis / ACB

Ist hier jemand dabei? Mich dünkt der Kurs interessant, allerdings stellt sich mir die Frage, ob das Unternehmen nicht etwas viel am Hals hat mit seinen Grossinvestitionen?

Z.B.bei CGC gefiel mir der Verlauf recht gut, ich sorge mich zwar, weil sie an die US-Börse wollen. Das ist teuer und falls dort dann doch mal wieder ein Verbot befohlen wird, wäre das recht gefährlich für die Investierten. Trauen kann ich nicht mehr recht, wenn man dort Einzug hält. Nicht wegen CGC. Aber die wechselden Meinungen und Bestimmungen und Diktate dort, für diese Branche, dünken mich unabsehbar.

http://marijuanastocks.com/aurora-cannabis-inc-acbff-makes-strategic-investment-in-ctt-pharmaceutical/

 

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
CGC / ACB

@Lorenz

Ja, das sind auch etwas meine Bedenken. Der Start in NY ist heute:

SMITHS FALLS, ON, May 23, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to announce that it expects its common shares will begin trading under the ticker symbol "CGC" on the New York Stock Exchange (the "NYSE") tomorrow, May 24, 2018.

This listing follows a history of firsts for the Company including being the first publicly traded, federally regulated cannabis company in North America, and the first to be included in the S&P/TSX Composite index.

Die ACB machen ihre Sache auch gut, ich denke, da darf man schon zugreifen, wer Lust hat.

 

 

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 15.10.2018
Mitglied seit: 10.11.2015
Kommentare: 104
ACB/CRON

....sicher ist das mit Vorsicht zu geniessen. Als Cronos zur Nasdaq avisierte schoss der Kurs hoch - kaum dort ging es rasant bachab, da habe ich einen gewaltigen Schuh  voll rausgezogen. Es hiess die Leerverkäufer hätten sich dort ihr Mütchen gekühlt, mit Erfolg - grrrrrrr

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 09.10.2018
Mitglied seit: 16.04.2010
Kommentare: 1'402
Aurora / ACB

Es scheint aber, nun kommt Geld für die Kanadier:

https://www.auroramj.com/

Quelle:

http://marijuanastocks.com/aurora-cannabis-inc-acbff-retains-kcsa-strategic-communications-to-enhance-u-s-investor-and-media-outreach/

Aurora Cannabis Retains KCSA Strategic Communications to Enhance U.S. investor and Media Outreach

Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announced it has appointed retained KCSA Strategic Communications (“KCSA”), a leading New York -based communications firm, to support the Company’s strategic communications and investor relations efforts in the United States .

“With American investor interest in Aurora growing rapidly, and a number of significant corporate developments on the way, this is the right moment for us to amplify our outreach to multiple U.S. audiences,” said Cam Battley , Chief Corporate Officer. “Given Aurora’s status as a global leader in the cannabis sector, we are adding skilled resources, both internally and externally, to help us share the Company’s story of agility, innovation and execution with institutional and retail investors in the U.S. and around the world.”

KCSA will implement a comprehensive communications program aimed at further increasing awareness of Aurora across the U.S. institutional and retail investment communities. Since its inception nearly fifty years ago, KCSA has developed a strong reputation for its work representing public companies, including a growing roster of cannabis companies.

Phil Carlson , Managing Director of KCSA Strategic Communications, commented, “Aurora has a clear and well-executed strategy, aimed at building a fully integrated and well-diversified cannabis company that meets all the critical success factors to capitalize on the global cannabis opportunity, estimated at approximately US$140 billion at maturity1 for the medical market alone. With our extensive history of providing expert strategic communications counsel based on best practices and large networks, we believe we are the right partner for Aurora to introduce this compelling story to a broader audience of institutional and retail investors, as well as to media and other influencers.”

Milestone payment

The Company issued a total of 182,853 common shares of the Company to the vendors of CanvasRx for the achievement of certain performance milestones, pursuant to a share purchase agreement announced on August 10, 2016.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta , known as “Aurora Mountain”, and a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island. In January 2018 , Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Inc.

The Company’s wholly-owned subsidiary CanniMed Therapeutics Inc. (“CanniMed”) is Canada’s most experienced licensed producer of medical cannabis, with over 20,000 kg per annum in funded capacity. CanniMed forms the heart of Aurora’s Medical Cannabis Centre of Excellence, aimed at product and market development.

Aurora also owns Berlin -based Pedanios GmbH, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark . The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens.

Aurora holds a 25% ownership interest in Alcanna Inc. (“CLIQ”), one of Western Canada’s largest retail chains of liquor stores, who are developing a cannabis retail network in Western Canada . In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc, and holds 52.7% of Hempco Food and Fiber Inc. Aurora is also the cornerstone investor in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options to increase to majority ownership. Finally, the Company owns a 9.14% stake in CTT Pharmaceutical, an innovative product development company within the cannabis space.

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 09.10.2018
Mitglied seit: 16.04.2010
Kommentare: 1'402
ACB-News / CGC-News

Heute gesehen, zum Aussuchen - oder beides:

Aurora Cannabis signs distribution deal in Germany

2018-05-28 07:55 ET - News Release

 

Mr. Terry Booth reports

AURORA CANNABIS SIGNS AGREEMENT WITH HEINRICH KLENK GMBH & CO. KG

Aurora Cannabis Inc., through its wholly owned subsidiary Pedanios GmbH, has signed a collaboration agreement with Heinrich Klenk GmbH & Co. KG, one of Europe's largest medicinal plant companies. Klenk, whose products are carried in over 25,000 pharmacies throughout Germany and Europe, has been importing, exporting and processing medicinal plants and herbal raw materials for the pharmaceutical industry for over 90 years.

Under the terms of the agreement, Aurora has launched a new cannabis brand in Germany called Cannabis Klenk which is produced in Canada, imported by Pedanios, and sold to German pharmacies through Klenk's existing and wide-reaching pharmaceutical wholesale distribution network. Klenk has an unmatched reputation in Germany, both for the quality of its products, and for the reliability of its distribution network.

"Klenk is a fantastic partner for Aurora, enabling us to add to our already leading presence in the German market with one of the country's most widely recognized medicinal plant brands and most comprehensive distribution networks," said Neil Belot, chief global business development officer. "Operating for over 90 years, Klenk is one of the most trusted partners to the pharmaceutical wholesale and pharmacy sectors. This, we believe, will help further destigmatize the use of medical cannabis in Germany and accelerate growth. Klenk's decentralized distribution capabilities ensure short supply lines throughout the entire country, greatly increasing our market reach, while reducing the need to invest heavily in our own sales and fulfilment capabilities."

Klenk and its medicinal plant products are synonymous with quality and are made available across Germany and Europe through decades-long relationships with the leading European pharmaceutical wholesale distributors. Cannabis Klenk branded products are currently held in over 20 distribution hubs located across Germany to facilitate fast and uncomplicated access, as well as same-day delivery service to pharmacies where available.

About Aurora Cannabis Inc.

Aurora's wholly owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, known as Aurora Mountain, and a second 40,000-square-foot high-technology production facility known as Aurora Vie in Pointe-Claire, Que., on Montreal's West Island. In January, 2018, Aurora's 800,000-square-foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kilograms per annum of cannabis.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved

 

Canopy Growth's Quebec JV receives licence to grow pot

2018-05-28 06:23 ET - News Release

 

Mr. Mark Zekulin reports

VERT IS GROWING AGAIN: HEALTH CANADA GRANTS LICENCE TO VERT MIRABEL

Canopy Growth Corp. and Les Serres Stephane Bertrand Inc.'s joint business Les Serres Vert Cannabis Inc. (Vert Mirabel) received a cultivation licence from Health Canada on Friday, May 25, 2018. This establishes the 10th licenced production facility under the Canopy in Canada, moving the company officially into double digits. The company also possesses a sales-only licence located in Toronto.

The 700,000-square-foot Vert Mirabel greenhouse is licensed for an initial 40,000 square feet of growing space, increasing Canopy Growth's production footprint in Quebec and confirming its commitment to growing high-quality, made-in-Quebec cannabis to serve Quebeckers and ensure a strong offering to combat the illicit market in Quebec.

"We've been focused on building an industry-leading growing platform across Canada and this licence is our latest successful step as we execute our vision for a reliable supply chain for Canadians," said Mark Zekulin, president, Canopy Growth. "Vert Mirabel is a shared achievement and we are excited to see the execution demonstrated by Mon. Bertrand, his family and their entire team. Canopy Growth shares their deep commitment to a responsible and productive cannabis industry in Quebec."

"Now the real fun begins. We're excited to start applying our 27 years in greenhouse production and our expertise in organic tomato production to the cannabis plant," said Stephane Bertrand, executive director, Les Serres Stephane Bertand Inc. "We're proud and excited to be working alongside Canopy Growth to establish this important production site in Quebec."

In total, Canopy Growth's licensed growing space has tripled in calendar 2018 to more than 2.4 million square feet and remains on path to exceed 5.6 million square feet of domestic growing space to support medical and recreational customers from coast-to-coast.

Here's to future growth (in la belle province).

About Canopy Growth Corp.

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms.

Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eight cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The company has operations in seven countries across four continents.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
ACB-Nesw / CGC-News

@Lorenz

Du hast Recht, man sollte Aurora auch nicht aus den Augen lassen, ich habe sie. (Bei CGC/WEED) bin ich seit dem US-Börsenstart mal weg).

 

Aurora Cannabis Launches New Cannabis Product Line – Aurora Frost

Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announces the launch of new product line called Aurora Frost . This new dried cannabis product line represents the highest potency offering of any Aurora product launched to date at over 35% THC.

Aurora Frost products are produced from premium whole flower. The products, generally known throughout the industry as kief, consist primarily of trichomes, the resinous glands rich in active pharmaceutical ingredients, including terpenes, flavonoids, and cannabinoids, such as THC and CBD.

Aurora’s in-house technology team successfully developed a new and proprietary technology used to efficiently produce high volume, GMP compliant, Aurora Frost products, based on a process that finely trims the trichomes from the cannabis flower.

Beginning today, Aurora Frost is shipping in convenient, child-safe, certified glass bottles. Products are sold in one gram increments, priced at $35 per gram ( $25 per gram for compassionate pricing patients). Like all Aurora products, Aurora Frost comes with publicly available third party independent laboratory results on potency, terpene profile, and contaminant analysis.

“Successfully developing a proprietary, fine trimming and GMP compliant technology needed to produce these high-quality products at commercial scale, provides us with a remarkable advantage in addressing this niche of the cannabis market,” said Terry Booth , CEO. “Aurora now makes this high potency medical cannabis available to its patients, reflecting the Aurora Standard of innovation and patient care.”

 

SMITHS FALLS, ON, May 30, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to announce that the Company has acquired Daddy Cann Lesotho PTY Ltd., trading as Highlands ("Highlands").

Based in the Kingdom of Lesotho ("Lesotho"), Highlands holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and its resin. Lesotho is a high altitude mountainous kingdom that boasts over 300 days of sunshine per year and was the first African nation to legalize medical cannabis in 2017. It has ideal humidity and growing conditions for greenhouse cultivation. Together with very low operating and resource costs, this places Canopy Growth in a position to produce large quantities of high quality medical cannabis at a low cost. Lesotho is also strategically positioned for the future medical cannabis economy of Southern Africa including the potential market of South Africa, with a population of over 55 million people, where medical cannabis laws are being developed.

"Lesotho is Canopy Growth's first step into Africa and we look forward to working with the strong local team at Highlands to establish production and distribution capabilities consistent with Canopy's global standard for high-quality, regulated medical cannabis products," said Mark Zekulin, President, Canopy Growth.

Combining the domestic and regional knowledge of Highlands with the global experience and expertise of Canopy Growth is the latest example of the Company establishing a meaningful local presence. With the objective of future local production to serve the regional market, these operations are part of Canopy Growth's commitment to the Lesotho economy including supporting job creation and lasting community engagement.

All key members of Highlands's management team will continue to lead the organization as part of the Canopy Growth family.  

"We're excited to join the Canopy Growth family and bring together our strong entrepreneurial experience and local knowledge in the region with Canopy Growth's track record and quality standards in the global medical cannabis industry," said Jody Aufrichtig, Founder, Highlands. "Lesotho and Southern Africa have enormous potential and we look forward to building a responsible medical cannabis business across the region."

Under the terms of the agreement, the Company issued 666,362 common shares in the capital of the Company to the sole shareholder of Highlands on closing and, subject to meeting certain milestones, the Company will issue up to an additional 333,281 common shares to the sole shareholder of Highlands for a total of up to 999,643 common shares based on the 30 day volume weighted average price of $28.763 of Canopy Growth's common shares on the TSX as of May 11, 2018. The total value of the consideration payable by the Company under the terms of the agreement is approximately $28.8 million.

This marks the fifth continent of operations for Canopy Growth who has market presence in North and South America, Oceania, Europe, and now Africa.

Here's to Future Growth (in Southern Africa).

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 25.09.2018
Mitglied seit: 06.06.2011
Kommentare: 677
ACB-Info

 

Dies wollte ich noch mitteilen:

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event through VirtualInvestorConferences.com

EDMONTON, Alberta, June 5, 2018 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that Cam Battley, Chief Corporate Officer will present live at VirtualInvestorConferences.com on June 7, 2018.

DATE: Thursday, June 7, 2018
TIME: 12:00 PM ET
LINK: https://tinyurl.com/0618prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Recent Company Highlights

  • Aurora Cannabis to Acquire MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted, in the money basis.
  • Launched a new product line called Aurora Frost. This new dried cannabis product line represents the highest potency offering of any Aurora product launched to date at over 35% THC.
  • The Company, through its wholly owned subsidiary Pedanios GmbH, has signed a collaboration agreement with Heinrich Klenk GmbH & Co. KG ("Klenk"), one of Europe's largest medicinal plant companies. Under the terms of the agreement, Aurora has launched a new cannabis brand in Germany called "Cannabis Klenk" which is produced in Canada, imported by Pedanios, and sold to German pharmacies through Klenk's existing and wide-reaching pharmaceutical wholesale distribution network.
  • Aurora is acquiring an initial 9.14% ownership interest in and CTT Pharmaceutical Holdings Inc, a global leader in the development of dose specific fast dissolving oral thin film wafers that provide a quick release, smoke-free delivery of medical cannabis or other active ingredients.

The Cannabis Virtual Investor Conference on June 7, 2018 is made possible by a partnership between KCSA Strategic Communications and VirtualInvestorConferences.com.  Learn more about the event at www.VirtualInvestorConferences.com.

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 15.10.2018
Mitglied seit: 10.11.2015
Kommentare: 104
Niederlage für Trudeau -

Niederlage für Trudeau - Konservativer wird Premierminister von Ontario

Ontario ist die bevölkerungsreichste Provinz Kanadas. Wer dort regiert, hat starken Einfluss auf die Politik des Landes.

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 09.10.2018
Mitglied seit: 16.04.2010
Kommentare: 1'402
Info-ACB

@ petra

Wolltest bestimmt was einfügen ?

Ich habe hier noch eine Info von heute:

Aurora Cannabis pleased with passage of Bill C-45

2018-06-08 04:40 ET - News Release

Mr. Terry Booth reports

AURORA CANNABIS WELCOMES HISTORIC SENATE VOTE TO LEGALIZE THE ADULT USAGE OF CANNABIS IN CANADA

Aurora Cannabis Inc. has commented on June 7, 2018, Canadian Senate vote in favour of Bill C-45, which governs the legalization of the adult consumer use of cannabis.

"This truly is a monumental day for Canada and the cannabis movement, with the ground-breaking Senate vote to pass Bill C-45 representing a major milestone, strengthening our global leadership in the cannabis sector, and making this country the first in the Group of Seven Nations (G7) to take this historic step," said Terry Booth, CEO. "We applaud the government's intelligent and rational public policy, initiating wholesale legislative changes - focused on clearly defined objectives - to reduce the negative impact of prohibition, while establishing a well-regulated system designed to protect public health and public safety. We must also salute and congratulate the advocates, the activists and the passionate who for decades, and often at great personal risk, spoke up, sat in, appealed laws, wrote new ones, ran studies, educated, and changed perceptions towards ending criminal prohibition."

"We are very pleased with today's vote, but more important work remains, particularly with respect to how our industry is allowed to operate and profile itself in order to meet Canadian adult consumer expectations," added Mr. Booth. "In addition, with legalization alone, the burden of prior non-violent cannabis-related convictions and charges will continue to carry a significant and unacceptable negative impact on many Canadians, disproportionately affecting individuals from marginalized populations. Aurora believes the government must now urgently consider amnesty for non-violent cannabis-related offenses, and will continue advocating on this important topic. Furthermore, we will continue our advocacy to obtain tax-exempt status for medical cannabis in support of Canada's patients whose quality of life has greatly improved through cannabis-based therapies. Medical cannabis currently is the sole prescribed medicine in Canada upon which any tax is charged, and we will continue our pursuit to correct this oversight."

Mr. Booth concluded, "With the implementation of Bill C-45 around the corner, we will continue our high-paced execution and deliver innovations, industry-leading customer care, and rapidly growing production capacity to this significant and exciting market. We will bring the Aurora Standard to the adult consumer market, delivering a uniquely satisfying customer experience."

 

Gestern:

 

Aurora Cannabis Enters into Global Softgel Business with Capcium Inc.

Strategic Investment Secures 19.99% Ownership of a Softgel Production Leader

EDMONTON, June 7, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Capcium Inc. ("Capcium") announced today that the companies have signed a strategic agreement to produce high quality cannabis-based softgels for patients.  Additionally, Aurora has acquired a 19.99% ownership interest in Capcium by way of a non-brokered private placement for consideration of $10 million.

Capcium, a privately-owned Montreal-based global leader in softgel manufacturing, has emerged as one of the leading manufacturers in the cannabis industry. Production of high-precision dosage controlled softgels is an extensive and complex process. Capcium, through its pharmaceutical and encapsulation experience, has developed expertise that is ready to be applied to the cannabis industry and deliver high-volume production capacity.

Capcium intends to use the proceeds from the Aurora investment to expand its cutting-edge cannabis softgel manufacturing business, which includes the construction and operation of a large, state-of-the-art facility, to be completed in Q4, 2019.

In advance of this new Capcium facility, and to accelerate time to market, Capcium and Aurora have agreed to immediately establish a high-volume, state-of-the-art softgel manufacturing operation at Aurora Vie, the Company's cannabis production facility in Pointe-Claire, Québec. Softgel sales from this facility are anticipated to commence (subject to Health Canada approval) by the end of Summer 2018. Capcium will be the exclusive manufacturer of Aurora's North American cannabis softgel products. The agreement also contemplates Capcium being the company's preferred global manufacturer of softgel cannabis products. 

Management Commentary

"This investment in Capcium reflects our strategic objective to further expand our differentiated, higher-margin product offerings," said Terry Booth, CEO of Aurora. "Capcium's extensive know-how has enabled it to develop an advanced technology for the high-volume production of cannabis-based softgels. This provides us with a strong competitive advantage, positioning us well to build a leading position in the production and sale of value-added cannabis products globally. We are proud that Aurora quickly is becoming the partner of choice in the cannabis industry, and we look forward to capitalizing with Capcium on the significant opportunity that softgels represent."

Sylvain Duvernay, CEO of Capcium, added, "Teaming up with what we believe to be the most innovative Licensed Producer with excellent international distribution channels, greatly enhances our growth prospects. We are delighted that Aurora and Capcium will become long-term partners, and look forward to bringing Québec made softgel cannabis products to Canada and to the global markets."

Aurora and Capcium believe the benefits of the transaction are significant for all shareholders. Aurora's brand leadership, quality products, customer care, innovation and deep product knowledge will be a strong complement to Capcium's well-established softgel manufacturing expertise. This deal will establish Québec as a world leader for cannabis value added products by leveraging the experience and expertise of two innovative companies with Québec operations, while creating highly-skilled Québec-based employment in the rapidly expanding cannabis sector.

Terms of the Investment

Aurora has made an initial $10 million investment in Capcium by way of a non-brokered private placement. The consideration paid by Aurora consists of $500,000 in cash and $9.5 in million common shares of Aurora at a five-day volume weighted average trading price of Aurora's Common Shares on the Toronto Stock Exchange (the "TSX") for the period ended June 6, 2018. Upon completion of the investment, Aurora will own approximately 19.99% of the issued and outstanding common shares of Capcium.

The private placement is subject to the final approval of the TSX, and is not subject to any financing or due diligence conditions.

About Aurora

Aurora's wholly-owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", and a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island. In January 2018, Aurora's 800,000 square foot flagship cultivation facility, Aurora Sky, located at the EdmontonInternational Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Inc.

The Company's wholly-owned subsidiary CanniMed Therapeutics Inc. ("CanniMed") is Canada's most experienced licensed producer of medical cannabis, with over 20,000 kg per annum in funded capacity. CanniMed forms the heart of Aurora's Medical Cannabis Centre of Excellence, aimed at product and market development.

Aurora owns Berlin-based Pedanios GmbH, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and state-of-the-art indoor gardening appliances for the cultivation of organic microgreens.

Aurora holds a 25% ownership interest in Alcanna Inc. ("CLIQ"), one of Western Canada's largest retail chains of liquor stores. The Company holds approximately 17.02% of the issued shares in leading extraction technology company Radient Technologies Inc, and holds 52.7% of Hempco Food and Fiber Inc. Aurora is also the cornerstone investor in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options to increase to majority ownership. Finally, the Company owns a 9.14% stake in CTT Pharmaceutical, an innovative product development company within the cannabis space.

Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index

About Capcium

Capcium Inc. is a Montreal based contract manufacturing platform specializing in softgel encapsulation. Capcium is transforming the cannabis industry by providing high-value, high quality cannabis products. Capcium presently holds a nutraceutical license from Health Canada and will soon apply to be fully licensed for cannabis in its new state-of-the-art manufacturing facility in Pointe Claire, Quebec.

 

 

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 15.10.2018
Mitglied seit: 10.11.2015
Kommentare: 104
@Lorenz

Eigentlich nicht....es war nur etwas Unruhe in den kanadischen Foren wegen diesen Wahlen - und bei mir auch. Aber heute hat Herr T. etwas von sich gegeben, was eher beruhigt, allerdings bei ihm weiss man nie....

Trump says he is likely to support ending federal ban on marijuana

https://www.msn.com/en-ca/news/politics/trump-says-he-is-likely-to-support-ending-federal-ban-on-marijuana/ar-AAyoK2p?ocid=spartanntp

 

...und das ist natürlich erfreulich - thanx

Aurora Cannabis Inc. has commented on June 7, 2018, Canadian Senate vote in favour of Bill C-45, which governs the legalization of the adult consumer use of cannabis.

Seiten